A number of studies have shown that bladder cancer cells harboring FGFR3 hyperactivating mutations and FGFR3-TACC3 fusion are responsive to FGFR3 inhibition [52,53,54,55]. Here, FGFR3 is linked to urinary bladder carcinoma.